Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
Jun 8, 2022 → Apr 23, 2023
NCT ID
NCT04485039About Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet
Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet is a approved stage product being developed by SIGA Technologies for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT04485039. Target conditions include Smallpox.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485039 | Approved | Completed |
Competing Products
20 competing products in Smallpox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Smallpox vaccine, LISTER strain, from chick embryo cells | Sanofi | Phase 2 | 51 |
| MVA (smallpox vaccine) | Sanofi | Phase 1 | 32 |
| ACAM3000 MVA Vaccine | Sanofi | Phase 1 | 32 |
| MVA Smallpox vaccine + Placebo | Sanofi | Phase 2 | 51 |
| ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax | Sanofi | Phase 2 | 51 |
| IMVAMUNE (MVA-BN) | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN | Bavarian Nordic | Phase 1 | 30 |
| IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| FD MVA-BN | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE® | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN® (IMVAMUNE) + Placebo | Bavarian Nordic | Phase 2 | 49 |
| Elstree-BN | Bavarian Nordic | Phase 1 | 30 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 69 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| ACAM2000® smallpox vaccine | Emergent BioSolutions | Pre-clinical | 15 |
| Brincidofovir | Emergent BioSolutions | Phase 1 | 25 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 77 |